MedTrace Logo

Economic Evaluation of Baroreceptor STIMulation for the Treatment of Resistant HyperTensioN

NCT02364310 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2022-09-01

No results posted yet for this study

Summary

Medico-economics assessment (cost-effectiveness) of the unilateral carotid barostimulation with Barostim NeoTM compared to usual care in patients with resistant hypertension (multicenter randomized, PROBE trial), followed-up for 12 months, with a lifetime-long modeling.

Conditions

Interventions

DEVICE

Baroreceptor stimulation with Barostim Neo TM

Sponsors & Collaborators

  • Pr Patrick ROSSIGNOL

    lead OTHER

Principal Investigators

  • Patrick ROSSIGNOL, Prof · CHRU Nancy

  • Michel AZIZI, Prof · APHP-HEGP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2021-06-22
Completion
2021-06-22

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02364310 on ClinicalTrials.gov